Table of Content - Intravenous Solution Market Trends, Size | Industry Analysis, 2032

Market Segmentation Tab

Intravenous Solution Nutrition Type Outlook (USD Million, 2018-2030)

Total Parenteral Nutrition

Peripheral Parenteral Nutrition

Intravenous Solution Bag Type Outlook (USD Million, 2018-2030)

Large Volume Bags (>250 ml)

Small Volume Bags (<250 ml)

Intravenous Solution Nutritional Content Outlook (USD Million, 2018-2030)

Amino Acid Solution

Carbohydrates

Vitamins & Minerals

Parenteral Lipid Emulsion

Intravenous Solution End User Outlook (USD Million, 2018-2030)

Hospital & Clinics

Ambulatory Surgical Centers

Home Care

Intravenous Solution Regional Outlook (USD Million, 2018-2030)

North America Outlook (USD Million, 2018-2030)
- North America Intravenous Solution by Nutrition Type
  - Total Parenteral Nutrition
  - Peripheral Parenteral Nutrition
- North America Intravenous Solution by Bag Type
  - Large Volume Bags (>250 ml)
  - Small Volume Bags (<250 ml)
- North America Intravenous Solution by Nutritional Content
  - Amino Acid Solution
  - Carbohydrates
  - Vitamins & Minerals
  - Parenteral Lipid Emulsion
- North America Intravenous Solution by End User
  - Hospital & Clinics
  - Ambulatory Surgical Centers
  - Home Care
- US Outlook (USD Million, 2018-2030)
- US Intravenous Solution by Nutrition Type
  - Total Parenteral Nutrition
  - Peripheral Parenteral Nutrition
- US Intravenous Solution by Bag Type
  - Large Volume Bags (>250 ml)
  - Small Volume Bags (<250 ml)
- US Intravenous Solution by Nutritional Content
  - Amino Acid Solution
  - Carbohydrates
  - Vitamins & Minerals
  - Parenteral Lipid Emulsion
- US Intravenous Solution by End User
  - Hospital & Clinics
  - Ambulatory Surgical Centers
  - Home Care
- CANADA Outlook (USD Million, 2018-2030)
- CANADA Intravenous Solution by Nutrition Type
  - Total Parenteral Nutrition
  - Peripheral Parenteral Nutrition
- CANADA Intravenous Solution by Bag Type
  - Large Volume Bags (>250 ml)
  - Small Volume Bags (<250 ml)
- CANADA Intravenous Solution by Nutritional Content
  - Amino Acid Solution
  - Carbohydrates
  - Vitamins & Minerals
  - Parenteral Lipid Emulsion
- CANADA Intravenous Solution by End User
  - Hospital & Clinics
  - Ambulatory Surgical Centers
  - Home Care
- Europe Outlook (USD Million, 2018-2030)
  - Europe Intravenous Solution by Nutrition Type
    - Total Parenteral Nutrition
    - Peripheral Parenteral Nutrition
  - Europe Intravenous Solution by Bag Type
    - Large Volume Bags (>250 ml)
    - Small Volume Bags (<250 ml)
  - Europe Intravenous Solution by Nutritional Content
    - Amino Acid Solution
    - Carbohydrates
    - Vitamins & Minerals
    - Parenteral Lipid Emulsion
  - Europe Intravenous Solution by End User
    - Hospital & Clinics
    - Ambulatory Surgical Centers
    - Home Care
  - Germany Outlook (USD Million, 2018-2030)
  - Germany Intravenous Solution by Nutrition Type
    - Total Parenteral Nutrition
    - Peripheral Parenteral Nutrition
  - Germany Intravenous Solution by Bag Type
    - Large Volume Bags (>250 ml)
    - Small Volume Bags (<250 ml)
  - Germany Intravenous Solution by Nutritional Content
    - Amino Acid Solution
    - Carbohydrates
    - Vitamins & Minerals
    - Parenteral Lipid Emulsion
  - Germany Intravenous Solution by End User
    - Hospital & Clinics
    - Ambulatory Surgical Centers
    - Home Care
  - France Outlook (USD Million, 2018-2030)
  - France Intravenous Solution by Nutrition Type
    - Total Parenteral Nutrition
    - Peripheral Parenteral Nutrition
  - France Intravenous Solution by Bag Type
    - Large Volume Bags (>250 ml)
    - Small Volume Bags (<250 ml)
  - France Intravenous Solution by Nutritional Content
    - Amino Acid Solution
    - Carbohydrates
    - Vitamins & Minerals
    - Parenteral Lipid Emulsion
  - France Intravenous Solution by End User
    - Hospital & Clinics
    - Ambulatory Surgical Centers
    - Home Care
  - UK Outlook (USD Million, 2018-2030)
  - UK Intravenous Solution by Nutrition Type
    - Total Parenteral Nutrition
    - Peripheral Parenteral Nutrition
  - UK Intravenous Solution by Bag Type
    - Large Volume Bags (>250 ml)
    - Small Volume Bags (<250 ml)
  - UK Intravenous Solution by Nutritional Content
    - Amino Acid Solution
    - Carbohydrates
    - Vitamins & Minerals
    - Parenteral Lipid Emulsion
  - UK Intravenous Solution by End User
    - Hospital & Clinics
    - Ambulatory Surgical Centers
    - Home Care
  - ITALY Outlook (USD Million, 2018-2030)
  - ITALY Intravenous Solution by Nutrition Type
    - Total Parenteral Nutrition
    - Peripheral Parenteral Nutrition
  - ITALY Intravenous Solution by Bag Type
    - Large Volume Bags (>250 ml)
    - Small Volume Bags (<250 ml)
  - ITALY Intravenous Solution by Nutritional Content
    - Amino Acid Solution
    - Carbohydrates
    - Vitamins & Minerals
    - Parenteral Lipid Emulsion
  - ITALY Intravenous Solution by End User
    - Hospital & Clinics
    - Ambulatory Surgical Centers
    - Home Care
  - SPAIN Outlook (USD Million, 2018-2030)
  - Spain Intravenous Solution by Nutrition Type
    - Total Parenteral Nutrition
    - Peripheral Parenteral Nutrition
  - Spain Intravenous Solution by Bag Type
    - Large Volume Bags (>250 ml)
    - Small Volume Bags (<250 ml)
  - Spain Intravenous Solution by Nutritional Content
    - Amino Acid Solution
    - Carbohydrates
    - Vitamins & Minerals
    - Parenteral Lipid Emulsion
  - Spain Intravenous Solution by End User
    - Hospital & Clinics
    - Ambulatory Surgical Centers
    - Home Care
  - Rest Of Europe Outlook (USD Million, 2018-2030)
  - Rest Of Europe Intravenous Solution by Nutrition Type
    - Total Parenteral Nutrition
    - Peripheral Parenteral Nutrition
  - REST OF EUROPE Intravenous Solution by Bag Type
    - Large Volume Bags (>250 ml)
    - Small Volume Bags (<250 ml)
  - REST OF EUROPE Intravenous Solution by Nutritional Content
    - Amino Acid Solution
    - Carbohydrates
    - Vitamins & Minerals
    - Parenteral Lipid Emulsion
  - REST OF EUROPE Intravenous Solution by End User
    - Hospital & Clinics
    - Ambulatory Surgical Centers
    - Home Care
  - Asia-Pacific Outlook (USD Million, 2018-2030)
    - Asia-Pacific Intravenous Solution by Nutrition Type
      - Total Parenteral Nutrition
      - Peripheral Parenteral Nutrition
    - Asia-Pacific Intravenous Solution by Bag Type
      - Large Volume Bags (>250 ml)
      - Small Volume Bags (<250 ml)
    - Asia-Pacific Intravenous Solution by Nutritional Content
      - Amino Acid Solution
      - Carbohydrates
      - Vitamins & Minerals
      - Parenteral Lipid Emulsion
    - Asia-Pacific Intravenous Solution by End User
      - Hospital & Clinics
      - Ambulatory Surgical Centers
      - Home Care
    - China Outlook (USD Million, 2018-2030)
    - China Intravenous Solution by Nutrition Type
      - Total Parenteral Nutrition
      - Peripheral Parenteral Nutrition
    - China Intravenous Solution by Bag Type
      - Large Volume Bags (>250 ml)
      - Small Volume Bags (<250 ml)
    - China Intravenous Solution by Nutritional Content
      - Amino Acid Solution
      - Carbohydrates
      - Vitamins & Minerals
      - Parenteral Lipid Emulsion
    - China Intravenous Solution by End User
      - Hospital & Clinics
      - Ambulatory Surgical Centers
      - Home Care
    - Japan Outlook (USD Million, 2018-2030)
    - Japan Intravenous Solution by Nutrition Type
      - Total Parenteral Nutrition
      - Peripheral Parenteral Nutrition
    - Japan Intravenous Solution by Bag Type
      - Large Volume Bags (>250 ml)
      - Small Volume Bags (<250 ml)
    - Japan Intravenous Solution by Nutritional Content
      - Amino Acid Solution
      - Carbohydrates
      - Vitamins & Minerals
      - Parenteral Lipid Emulsion
    - Japan Intravenous Solution by End User
      - Hospital & Clinics
      - Ambulatory Surgical Centers
      - Home Care
    - India Outlook (USD Million, 2018-2030)
    - India Intravenous Solution by Nutrition Type
      - Total Parenteral Nutrition
      - Peripheral Parenteral Nutrition
    - India Intravenous Solution by Bag Type
      - Large Volume Bags (>250 ml)
      - Small Volume Bags (<250 ml)
    - India Intravenous Solution by Nutritional Content
      - Amino Acid Solution
      - Carbohydrates
      - Vitamins & Minerals
      - Parenteral Lipid Emulsion
    - India Intravenous Solution by End User
      - Hospital & Clinics
      - Ambulatory Surgical Centers
      - Home Care
    - Australia Outlook (USD Million, 2018-2030)
    - Australia Intravenous Solution by Nutrition Type
      - Total Parenteral Nutrition
      - Peripheral Parenteral Nutrition
    - Australia Intravenous Solution by Bag Type
      - Large Volume Bags (>250 ml)
      - Small Volume Bags (<250 ml)
    - Australia Intravenous Solution by Nutritional Content
      - Amino Acid Solution
      - Carbohydrates
      - Vitamins & Minerals
      - Parenteral Lipid Emulsion
    - Australia Intravenous Solution by End User
      - Hospital & Clinics
      - Ambulatory Surgical Centers
      - Home Care
    - Rest of Asia-Pacific Outlook (USD Million, 2018-2030)
    - Rest of Asia-Pacific Intravenous Solution by Nutrition Type
      - Total Parenteral Nutrition
      - Peripheral Parenteral Nutrition
    - Rest of Asia-Pacific Intravenous Solution by Bag Type
      - Large Volume Bags (>250 ml)
      - Small Volume Bags (<250 ml)
    - Rest of Asia-Pacific Intravenous Solution by Nutritional Content
      - Amino Acid Solution
      - Carbohydrates
      - Vitamins & Minerals
      - Parenteral Lipid Emulsion
    - Rest of Asia-Pacific Intravenous Solution by End User
      - Hospital & Clinics
      - Ambulatory Surgical Centers
      - Home Care
    - Rest of the World Outlook (USD Million, 2018-2030)
      - Rest of the World Intravenous Solution by Nutrition Type
        
        Total Parenteral Nutrition
        
        Peripheral Parenteral Nutrition
      - Rest of the World Intravenous Solution by Bag Type
        
        Large Volume Bags (>250 ml)
        
        Small Volume Bags (<250 ml)
      - Rest of the World Intravenous Solution by Nutritional Content
        
        Amino Acid Solution
        
        Carbohydrates
        
        Vitamins & Minerals
        
        Parenteral Lipid Emulsion
      - Rest of the World Intravenous Solution by End User
        
        Hospital & Clinics
        
        Ambulatory Surgical Centers
        
        Home Care
      - Middle East Outlook (USD Million, 2018-2030)
      - Middle East Intravenous Solution by Nutrition Type
        
        Total Parenteral Nutrition
        
        Peripheral Parenteral Nutrition
      - Middle East Intravenous Solution by Bag Type
        
        Large Volume Bags (>250 ml)
        
        Small Volume Bags (<250 ml)
      - Middle East Intravenous Solution by Nutritional Content
        
        Amino Acid Solution
        
        Carbohydrates
        
        Vitamins & Minerals
        
        Parenteral Lipid Emulsion
      - Middle East Intravenous Solution by End User
        
        Hospital & Clinics
        
        Ambulatory Surgical Centers
        
        Home Care
      - Africa Outlook (USD Million, 2018-2030)
      - Africa Intravenous Solution by Nutrition Type
        
        Total Parenteral Nutrition
        
        Peripheral Parenteral Nutrition
      - Africa Intravenous Solution by Bag Type
        
        Large Volume Bags (>250 ml)
        
        Small Volume Bags (<250 ml)
      - Africa Intravenous Solution by Nutritional Content
        
        Amino Acid Solution
        
        Carbohydrates
        
        Vitamins & Minerals
        
        Parenteral Lipid Emulsion
      - Africa Intravenous Solution by End User
        
        Hospital & Clinics
        
        Ambulatory Surgical Centers
        
        Home Care
      - Latin America Outlook (USD Million, 2018-2030)
      - Latin America Intravenous Solution by Nutrition Type
        
        Total Parenteral Nutrition
        
        Peripheral Parenteral Nutrition
      - Latin America Intravenous Solution by Bag Type
        
        Large Volume Bags (>250 ml)
        
        Small Volume Bags (<250 ml)
      - Latin America Intravenous Solution by Nutritional Content
        
        Amino Acid Solution
        
        Carbohydrates
        
        Vitamins & Minerals
        
        Parenteral Lipid Emulsion
      - Latin America Intravenous Solution by End User
        
        Hospital & Clinics
        
        Ambulatory Surgical Centers
        
        Home Care

Research Methodology on Intravenous Solution Market

1. Objective of the Study:

The main objective of this study is to understand the current market trends, drivers, and dynamics of the Intravenous (IV) Solution market and assess the potential of the Intravenous Solution market to enable the stakeholders in understanding the investment opportunities in the market.

2. Definition of Intravenous Solution:

An intravenous solution is a solution prepared to be delivered directly into the bloodstream via a vein. These solutions can be normal saline or other solutions containing glucose, electrolytes, and vitamins, and are used to replace lost body fluids or provide nutrients to the patient.

3. Research Philosophy:

The research philosophy adopted for this study is positivism. This philosophy is based on the notion that the truth can be established through the observation and analysis of the cause-effect relation of the particular phenomena under study.

4. Research Approach:

The study includes primary and secondary data collection and analysis. The secondary data sources used include press releases, the company’s official reports, world literature, and white papers. The secondary research involves gathering data from existing databases, reports, and other published literature. The primary research is conducted to validate the information gathered through secondary research and analyze the present market scenario.

The primary research interviews are conducted to obtain the insights of the market experts. Qualitative and quantitative research methodologies are adopted to understand and define the present market trends and get detailed information on the Intravenous solution market characteristics.

The qualitative methodologies used include focus group discussions, in-depth interviews, and feedback sessions. A brief description of the qualitative methodologies used is given below:

Focus Group Discussions:

This method is conducted to understand the market dynamics and to get insights into the Intravenous Solution market. The participants for this method consisted of industry experts and key opinion leaders (KOLs).

In-depth Interviews:

These interviews are conducted with the top management staff of the vendors operating in the Intravenous Solution market. The objective is to understand their opinion and insights about the Intravenous Solution market.

Feedback Sessions:

These sessions were conducted to get the opinion of industry experts and key opinion leaders about different aspects of the Intravenous Solution market.

The quantitative methodologies used in the study include market sizing, forecasting, regression analysis, and Monte Carlo simulation. A brief description of the quantitative methodologies used is given below:

Market Sizing:

The top-down and bottom-up approaches were used to size the global Intravenous Solution market. The market size is estimated by dividing the total addressable market into different segments and geographies.

Forecasting:

The forecasting technique is used to predict future trends in the Intravenous Solution market. The forecasting method is based on historical data, current market trends, and inputs from industry experts.

Regression Analysis:

The regression analysis is used to analyze the trends in the Intravenous Solution market. This is used to identify the cause-and-effect relationship of different factors influencing the market.

Monte Carlo Simulation:

The Monte Carlo simulation is used to evaluate the impact of different parameters on the Intravenous Solution market. This was used to identify the most likely outcome of the global Intravenous Solution market.

5. Data Collection Tools:

The data collection tools used for this study include primary and secondary research. The primary research involved conducting interviews with industry experts, key opinion leaders (KOLs), and other stakeholders. The contact details of the third-party data sources used to validate the data collected through primary and secondary research methodologies are mentioned in the Bibliography section of the report.

6. Sampling Techniques:

The sampling technique used in this study is two-stage sampling. In the first stage, the population sample was segmented into sub-samples based on geographies and end-user industries. This sample was then randomly selected for data collection in the second stage.

7. Variables:

The following are the variables used in the study:

Drivers: Government regulations, medical advances, and market consolidation.

Restraints: Shortage of healthcare professionals and high cost of machinery.

Opportunities: Increased demand for IV solutions, the introduction of new products and services, and growth in the geriatric population.

Challenges: Lack of awareness, regulatory constraints, and deficiencies in healthcare infrastructure.

8. Model Assumptions:

The assumptions used in the study are based on the insights gained from the primary research interviews with industry experts and KOLs.

9. Data Triangulation:

The dataset for this study is gathered from both primary and secondary sources. The data is triangulated to verify the reliability of the data gathered from each source and ensure that the data is factual and reliable.

10. Research Data Validation:

The research data is validated with the help of experts and KOLs in the Intravenous Solution market. The validation is done through primary research interviews. After collecting the primary data, a detailed analysis of the data is done to identify the accuracy of the data.

Leading companies partner with us for data-driven Insights

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY 14

2 MARKET INTRODUCTION 15

2.1 SCOPE OF THE STUDY 15

2.2 RESEARCH OBJECTIVE 15

2.3 MARKET STRUCTURE 15

2.4 ASSUMPTIONS & LIMITATIONS 16

3 RESEARCH METHODOLOGY 17

3.1 DATA MINING 17

3.2 SECONDARY RESEARCH 18

3.3 PRIMARY RESEARCH 19

3.4 BREAKDOWN OF PRIMARY RESPONDENTS 20

3.5 FORECASTING TECHNIQUES 21

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 21

3.6.1 BOTTOM-UP APPROACH 22

3.6.2 TOP-DOWN APPROACH 22

3.7 DATA TRIANGULATION 23

3.8 VALIDATION 23

4 MARKET DYNAMICS 24

4.1 OVERVIEW 24

4.2 DRIVERS 25

4.2.1 INCREASING PREVALENCE OF CHRONIC DISEASES 25

4.2.2 RISING INCIDENCES OF CHOLERA 25

4.2.3 GROWING ACCEPTANCE OF VITAMIN C INTRAVENOUS SOLUTIONS FOR COLORECTAL CANCER 25

4.3 RESTRAINT 26

4.3.1 PRESENCE OF STRINGENT GOVERNMENT REGULATIONS 26

4.4 OPPORTUNITY 27

4.4.1 RISING CONTINUOUS DEMAND FOR INTRAVENOUS SOLUTIONS 27

5 MARKET FACTOR ANALYSIS 28

5.1 VALUE CHAIN ANALYSIS 28

5.1.1 R&D AND DESIGNING 29

5.1.2 MANUFACTURING 29

5.1.3 DISTRIBUTION & SALES 29

5.1.4 POST-SALES MONITORING 29

5.2 PORTER'S FIVE FORCES MODEL 29

5.2.1 THREAT OF NEW ENTRANTS 30

5.2.2 BARGAINING POWER OF SUPPLIERS 30

5.2.3 THREAT OF SUBSTITUTES 31

5.2.4 BARGAINING POWER OF BUYERS 31

5.2.5 INTENSITY OF RIVALRY 31

5.3 COVID-19 IMPACT ANALYSIS 31

5.3.1 IMPACT ON THE SUPPLY CHAIN 31

5.3.2 IMPACT ON PRICING 31

5.3.3 IMPACT ON PRODUCTION 32

6 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE 33

6.1 OVERVIEW 33

6.2 PERIPHERAL PARENTERAL NUTRITION 34

6.3 TOTAL PARENTERAL NUTRITION 34

7 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE 35

7.1 OVERVIEW 35

7.2 LARGE VOLUME BAGS (>250 ML) 36

7.3 SMALL VOLUME BAGS (<250 ML) 36

8 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT 37

8.1 OVERVIEW 37

8.2 AMINO ACID SOLUTION 38

8.3 CARBOHYDRATES 38

8.4 VITAMINS & MINERALS 39

8.5 PARENTERAL LIPID EMULSION 39

8.6 OTHERS 40

9 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER 41

9.1 OVERVIEW 41

9.2 HOSPITAL & CLINICS 42

9.3 AMBULATORY SURGICAL CENTERS 42

9.4 HOME CARE 43

10 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET, BY REGION 44

10.1 OVERVIEW 44

10.2 NORTH AMERICA 46

10.2.1 US 48

10.2.2 CANADA 49

10.3 EUROPE 51

10.3.1 GERMANY 53

10.3.2 FRANCE 54

10.3.3 UK 56

10.3.4 ITALY 57

10.3.5 SPAIN 58

10.3.6 REST OF EUROPE 60

10.4 ASIA PACIFIC 62

10.4.1 CHINA 64

10.4.2 INDIA 66

10.4.3 INDONESIA 67

10.4.4 JAPAN 68

10.4.5 PHILIPPINES 70

10.4.6 THAILAND 71

10.4.7 SOUTH KOREA 72

10.4.8 AUSTRALIA 74

10.4.9 SINGAPORE 75

10.4.10 MALAYSIA 76

10.4.11 REST OF ASIA-PACIFIC 78

10.5 REST OF THE WORLD 80

10.5.1 MIDDLE EAST 82

10.5.2 AFRICA 83

10.5.3 LATIN AMERICA 85

11 COMPETITIVE LANDSCAPE 87

11.1 OVERVIEW 87

11.2 COMPETITIVE BENCHMARKING 89

11.3 COMPETITOR DASHBOARD 90

11.4 MAJOR GROWTH STRATEGY IN THE GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET 90

11.5 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET 91

11.6 KEY DEVELOPMENT ANALYSIS 91

11.7 KEY DEVELOPMENTS & GROWTH STRATEGIES 92

11.7.1 PRODUCT LAUNCH/PRODUCT APPROVAL 92

11.7.2 MERGER/ACQUISITION 92

11.7.3 PARTNERSHIP/AGREEMENT 93

11.7.4 EXPANSION/ INVESTMENT 93

12 COMPANY PROFILES 94

12.1 BAXTER INTERNATIONAL INC. 94

12.1.1 COMPANY OVERVIEW 94

12.1.2 FINANCIAL OVERVIEW 95

12.1.3 PRODUCTS/SERVICES OFFERED 96

12.1.4 KEY DEVELOPMENTS 96

12.1.5 SWOT ANALYSIS 97

12.1.6 KEY STRATEGIES 97

12.2 FRESENIUS KABI AG 98

12.2.1 COMPANY OVERVIEW 98

12.2.2 FINANCIAL OVERVIEW 98

12.2.3 PRODUCTS/SERVICES OFFERED 99

12.2.4 KEY DEVELOPMENTS 99

12.2.5 SWOT ANALYSIS 99

12.2.6 KEY STRATEGIES 100

12.3 B. BRAUN MELSUNGEN AG 101

12.3.1 COMPANY OVERVIEW 101

12.3.2 FINANCIAL OVERVIEW 102

12.3.3 PRODUCTS/SERVICES OFFERED 103

12.3.4 KEY DEVELOPMENTS 103

12.3.5 SWOT ANALYSIS 104

12.3.6 KEY STRATEGIES 104

12.4 ICU MEDICAL, INC. 105

12.4.1 COMPANY OVERVIEW 105

12.4.2 FINANCIAL OVERVIEW 105

12.4.3 PRODUCTS/SERVICES OFFERED 106

12.4.4 KEY DEVELOPMENTS 106

12.4.5 SWOT ANALYSIS 107

12.4.6 KEY STRATEGIES 107

12.5 PFIZER INC. 108

12.5.1 COMPANY OVERVIEW 108

12.5.2 FINANCIAL OVERVIEW 108

12.5.3 PRODUCTS/SERVICES OFFERED 109

12.5.4 KEY DEVELOPMENTS 109

12.5.5 SWOT ANALYSIS 109

12.5.6 KEY STRATEGIES 110

12.6 GRIFOLS, S.A. 111

12.6.1 COMPANY OVERVIEW 111

12.6.2 FINANCIAL OVERVIEW 111

12.6.3 PRODUCTS/SERVICES OFFERED 112

12.6.4 KEY DEVELOPMENTS 112

12.6.5 SWOT ANALYSIS 112

12.6.6 KEY STRATEGIES 113

12.7 TERUMO MEDICAL CORPORATION 114

12.7.1 COMPANY OVERVIEW 114

12.7.2 FINANCIAL OVERVIEW 115

12.7.3 PRODUCTS OFFERED 115

12.7.4 KEY DEVELOPMENTS 116

12.7.5 SWOT ANALYSIS 116

12.7.6 KEY STRATEGIES 116

12.8 OSTUKA PHARMACEUTICALS 117

12.8.1 COMPANY OVERVIEW 117

12.8.2 FINANCIAL OVERVIEW 117

12.8.3 PRODUCTS/SERVICES OFFERED 118

12.8.4 KEY DEVELOPMENTS 118

12.8.5 SWOT ANALYSIS 119

12.8.6 KEY STRATEGIES 119

12.9 AMANTA HEALTHCARE 120

12.9.1 COMPANY OVERVIEW 120

12.9.2 FINANCIAL OVERVIEW 120

12.9.3 PRODUCTS/SERVICES OFFERED 120

12.9.4 KEY DEVELOPMENTS 120

12.9.5 SWOT ANALYSIS 121

12.9.6 KEY STRATEGIES 121

12.10 AXA PARENTERALS 122

12.10.1 COMPANY OVERVIEW 122

12.10.2 FINANCIAL OVERVIEW 122

12.10.3 PRODUCTS/SERVICES OFFERED 122

12.10.4 KEY DEVELOPMENTS 122

12.10.5 SWOT ANALYSIS 123

12.10.6 KEY STRATEGIES 123

13 APPENDIX 124

13.1 REFERENCES 124

13.2 RELATED REPORTS 124

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 16

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 19

TABLE 3 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 33

TABLE 4 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET FOR PERIPHERAL PARENTERAL NUTRITION, BY REGION, 2022-2030 (USD MILLION) 34

TABLE 5 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET FOR TOTAL PARENTERAL NUTRITION, BY REGION, 2022-2030 (USD MILLION) 34

TABLE 6 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE,2022-2030 (USD MILLION) 35

TABLE 7 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET, FOR LARGE VOLUME BAGS (>250 ML), BY REGION 2022-2030 (USD MILLION) 36

TABLE 8 GLOBAL INTRAVENOUS SOLUTIONS MARKET, FOR SMALL VOLUME BAGS, BY REGION 2022-2030 (USD MILLION) 36

TABLE 9 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 37

TABLE 10 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET FOR AMINO ACID SOLUTION, BY REGION, 2022-2030 (USD MILLION) 38

TABLE 11 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET FOR CARBOHYDRATES, BY REGION, 2022-2030 (USD MILLION) 38

TABLE 12 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET FOR VITAMINS & MINERALS, BY REGION, 2022-2030 (USD MILLION) 39

TABLE 13 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET FOR PARENTERAL LIPID EMULSION, BY REGION, 2022-2030 (USD MILLION) 39

TABLE 14 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET FOR OTHERS, BY REGION, 2022-2030 (USD MILLION) 40

TABLE 15 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER 2022-2030 (USD MILLION) 41

TABLE 16 GLOBAL INTRAVENOUS (IV) SOLUTION MARKET FOR HOSPITAL & CLINICS, BY REGION, 2022-2030 (USD MILLION) 42

TABLE 17 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2022-2030 (USD MILLION) 42

TABLE 18 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET FOR HOME CARE, BY REGION, 2022-2030 (USD MILLION) 43

TABLE 19 GLOBAL: INTRAVENOUS (IV) SOLUTIONS MARKET, BY REGION, 2022-2030 (USD MILLION) 44

TABLE 20 NORTH AMERICA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION) 46

TABLE 21 NORTH AMERICA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 47

TABLE 22 NORTH AMERICA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 47

TABLE 23 NORTH AMERICA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 47

TABLE 24 NORTH AMERICA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 48

TABLE 25 US: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 48

TABLE 26 US: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 48

TABLE 27 US: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 49

TABLE 28 US: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 49

TABLE 29 CANADA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 49

TABLE 30 CANADA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 50

TABLE 31 CANADA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 50

TABLE 32 CANADA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 50

TABLE 33 EUROPE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION) 51

TABLE 34 EUROPE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 52

TABLE 35 EUROPE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 52

TABLE 36 EUROPE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 52

TABLE 37 EUROPE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 53

TABLE 38 GERMANY: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 53

TABLE 39 GERMANY: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 53

TABLE 40 GERMANY: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 54

TABLE 41 GERMANY: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 54

TABLE 42 FRANCE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 54

TABLE 43 FRANCE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 55

TABLE 44 FRANCE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 55

TABLE 45 FRANCE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 55

TABLE 46 UK: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 56

TABLE 47 UK: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 56

TABLE 48 UK: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 56

TABLE 49 UK: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 57

TABLE 50 ITALY: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 57

TABLE 51 ITALY: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 57

TABLE 52 ITALY: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 58

TABLE 53 ITALY: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 58

TABLE 54 SPAIN: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 58

TABLE 55 SPAIN: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 59

TABLE 56 SPAIN: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 59

TABLE 57 SPAIN: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 59

TABLE 58 REST OF EUROPE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 60

TABLE 59 RST OF EUROPE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 60

TABLE 60 REST OF EUROPE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 60

TABLE 61 REST OF EUROPE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 61

TABLE 62 ASIA-PACIFIC: INTRAVENOUS (IV) SOLUTIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION) 62

TABLE 63 ASIA-PACIFIC: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 63

TABLE 64 ASIA-PACFIC: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 63

TABLE 65 ASIA-PACIFIC: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 64

TABLE 66 ASA-PACIFIC: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 64

TABLE 67 CHINA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 64

TABLE 68 CHINA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 65

TABLE 69 CHINA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 65

TABLE 70 CHINA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 65

TABLE 71 INDIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 66

TABLE 72 INDIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 66

TABLE 73 INDIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 66

TABLE 74 INDIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 67

TABLE 75 INDONESIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 67

TABLE 76 INDONESIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 67

TABLE 77 INDONESIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 68

TABLE 78 INDONESIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 68

TABLE 79 JAPAN: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 68

TABLE 80 JAPAN: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 69

TABLE 81 JAPAN: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 69

TABLE 82 JAPAN: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 69

TABLE 83 PHILIPPINES: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 70

TABLE 84 PHILIPPINES: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 70

TABLE 85 PHILIPPINES: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 70

TABLE 86 PHILIPPINES: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 71

TABLE 87 THAILAND: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 71

TABLE 88 THAILAND: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 71

TABLE 89 THAILAND: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 72

TABLE 90 THAILAND: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 72

TABLE 91 SOUTH KOREA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 72

TABLE 92 SOUTH KOREA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 73

TABLE 93 SOUTH KOREA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 73

TABLE 94 SOUTH KOREA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 73

TABLE 95 AUSTRALIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 74

TABLE 96 AUSTRALIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 74

TABLE 97 AUSTRALIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 74

TABLE 98 AUSTRALIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 75

TABLE 99 SINGAPORE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 75

TABLE 100 SINGAPORE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 75

TABLE 101 SINGAPORE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 76

TABLE 102 SINGAPORE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 76

TABLE 103 MALAYSIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 76

TABLE 104 MALAYSIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 77

TABLE 105 MALAYSIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 77

TABLE 106 MALAYSIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 77

TABLE 107 REST OF ASIA-PACIFIC: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 78

TABLE 108 REST OF ASIA-PACIFIC: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 78

TABLE 109 REST OF ASIA-PACIFIC: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 78

TABLE 110 REST OF ASIA-PACIFIC: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 79

TABLE 111 REST OF THE WORLD: INTRAVENOUS (IV) SOLUTIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION) 80

TABLE 112 REST OF THE WORLD: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 81

TABLE 113 REST OF THE WORLD: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 81

TABLE 114 REST OF THE WROLD: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 81

TABLE 115 REST OF THE WORLD: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 82

TABLE 116 MIDDLE EAST: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 82

TABLE 117 MIDDLE EAST: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 82

TABLE 118 MIDDLE EAST: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 83

TABLE 119 MIDDLE EAST: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 83

TABLE 120 AFRICA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 83

TABLE 121 AFRICA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 84

TABLE 122 AFRICA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 84

TABLE 123 AFRICA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 84

TABLE 124 LATIN AMERICA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 85

TABLE 125 LATIN AMERICA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 85

TABLE 126 LATIN AMERICA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 85

TABLE 127 LATIN AMERICA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 86

TABLE 128 COMPETITOR DASHBOARD: GLOBAL INTRAVENOUS SOLUTIONS MARKET 90

TABLE 129 MOST ACTIVE PLAYERS IN THE GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET 91

TABLE 130 PRODUCT LAUNCH/PRODUCT APPROVAL 92

TABLE 131 MERGER/ACQUISITION 92

TABLE 132 PARTNERSHIP/AGREEMENT 93

TABLE 133 EXPANSION/ INVESTMENT 93

TABLE 134 BAXTER INTERNATIONAL INC.: PRODUCTS/SERVICES OFFERED 96

TABLE 135 FRESENIUS KABI AG: PRODUCTS/SERVICES OFFERED 99

TABLE 136 B. BRAUN MELSUNGEN AG: PRODUCTS/SERVICES OFFERED 103

TABLE 137 B. BRAUN MELSUNGEN AG: KEY DEVELOPMENTS 103

TABLE 138 ICU MEDICAL, INC: PRODUCTS/SERVICES OFFERED 106

TABLE 139 ICU MEDICAL, INC.: KEY DEVELOPMENTS 106

TABLE 140 PFIZER INC.: PRODUCTS/SERVICES OFFERED 109

TABLE 141 GRIFOLS, S.A.: PRODUCTS/SERVICES OFFERED 112

TABLE 142 GRIFOLS, S.A: KEY DEVELOPMENTS 112

TABLE 143 TERUMO MEDICAL CORPORATION: PRODUCTS/SERVICES OFFERED 115

TABLE 144 TERUMO MEDICAL CORPORATION: KEY DEVELOPMENTS 116

TABLE 145 OSTUKA PHARMACEUTICALS: PRODUCTS/SERVICES OFFERED 118

TABLE 146 OSTUKA PHARMACEUTICALS: KEY DEVELOPMENTS 118

TABLE 147 AMANTA HEALTHCARE: PRODUCTS/SERVICES OFFERED 120

TABLE 148 AXA PARENTERALS: PRODUCTS/SERVICES OFFERED 122

LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS 14

FIGURE 2 GLOBAL INTRAVENOUS (IV) SOLUTION MARKET 15

FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES 22

FIGURE 4 MARKET DYNAMICS: GLOBAL INTRAVENOUS SOLUTIONS MARKET 24

FIGURE 5 DRIVERS: IMPACT ANALYSIS 26

FIGURE 6 RESTRAINT: IMPACT ANALYSIS 27

FIGURE 7 VALUE CHAIN: GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET 28

FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL INTRAVENOUS SOLUTIONS MARKET 30

FIGURE 9 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 33

FIGURE 10 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 35

FIGURE 11 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 37

FIGURE 12 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 41

FIGURE 13 GLOBAL: INTRAVENOUS (IV) SOLUTIONS MARKET, BY REGION 2020 & 2028 (USD MILLION) 44

FIGURE 14 GLOBAL: INTRAVENOUS (IV) SOLUTIONS MARKET SHARE, BY REGION 2020 (%) 45

FIGURE 15 NORTH AMERICA: INTRAVENOUS (IV) SOLUTIONS MARKET SHARE, BY COUNTRY 2020 (%) 46

FIGURE 16 EUROPE: INTRAVENOUS (IV) SOLUTIONS MARKET SHARE, BY COUNTRY 2020 (%) 51

FIGURE 17 ASIA-PACIFIC: INTRAVENOUS (IV) SOLUTIONS MARKET SHARE, BY COUNTRY 2020 (%) 63

FIGURE 18 REST OF THE WORLD: INTRAVENOUS (IV) SOLUTIONS MARKET SHARE, BY COUNTRY 2020 (%) 80

FIGURE 19 MAJOR MANUFACTURERS IN THE GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET 88

FIGURE 20 BENCHMARKING OF MAJOR COMPETITORS 89

FIGURE 21 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET 90

FIGURE 22 GLOBAL INTRAVENOUS SOLUTIONS MARKET: COMPETITIVE LANDSCAPE 91

FIGURE 23 BAXTER INTERNATIONAL INC.: FINANCIAL OVERVIEW 95

FIGURE 24 BAXTER INTERNATIONAL INC.: SWOT ANALYSIS 97

FIGURE 25 FRESENIUS KABI AG: FINANCIAL OVERVIEW 98

FIGURE 26 FRESENIUS KABI AG: SWOT ANALYSIS 99

FIGURE 27 B. BRAUN MELSUNGEN AG: FINANCIAL OVERVIEW SNAPSHOT 102

FIGURE 28 B. BRAUN MELSUNGEN AG: SWOT ANALYSIS 104

FIGURE 29 ICU MEDICAL, INC.: FINANCIAL OVERVIEW 105

FIGURE 30 ICU MEDICAL, INC: SWOT ANALYSIS 107

FIGURE 31 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT 108

FIGURE 32 PFIZER INC: SWOT ANALYSIS 109

FIGURE 33 GRIFOLS, S.A.: FINANCIAL OVERVIEW 111

FIGURE 34 GRIFOLS, S.A.: SWOT ANALYSIS 112

FIGURE 35 TERUMO MEDICAL CORPORATION: FINANCIAL OVERVIEW SNAPSHOT 115

FIGURE 36 TERUMO MEDICAL CORPORATION: SWOT ANALYSIS 116

FIGURE 37 OTSUKA PHARMACEUTICAL CO., LTD: FINANCIAL OVERVIEW SNAPSHOT 117

FIGURE 38 OSTUKA PHARMACEUTICALS: SWOT ANALYSIS 119

FIGURE 39 AMANTA HEALTHCARE: SWOT ANALYSIS 121

FIGURE 40 AXA PARENTERALS: SWOT ANALYSIS 123

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

FEATURES	LICENCE TYPE
FEATURES	Single User	Multiuser Licence	Enterprise User
Price	$ 4,950	$ 5,950	$ 7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout The Organization.
Free Customization
Direct access to the Analyst
Deliverable Format
Deliverable Format
Platform Access
Discount on Your Next Purchase	10%	15%	10%
Printable Versions

Why Choose Market Research Future?

Leading companies partner with us for data-driven Insights